[1]
|
Tucker, M.A. and Goldstein, A.M. (2003) Melanoma etiology: Where are we? Oncogene, 22, 3042-3052.
http://dx.doi.org/10.1038/sj.onc.1206444
|
[2]
|
Chambers, A.F., Groom, A.C. and MacDonald, I.C. (2002) Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2, 563-572.
http://dx.doi.org/10.1038/nrc865
|
[3]
|
Gaggioli, C. and Sahai, E. (2007) Melanoma invasion— Current knowledge and future directions. Pigment Cell Research, 20, 161-172.
http://dx.doi.org/10.1111/j.1600-0749.2007.00378.x
|
[4]
|
Clark, W.H., Elder, D.E., Guerry, D., Epstein, M.N., Greene, M.H. and Van Horn, M. (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathology, 15, 1147-1165. http://dx.doi.org/10.1016/S0046-8177(84)80310-X
|
[5]
|
Song, Y.K., Billiar, T.R. and Lee, Y.J. (2002) Role of galectin-3 in breast cancer metastasis: Involvement of nitric oxide. American Journal of Pathology, 160, 1069-1075.
http://dx.doi.org/10.1016/S0002-9440(10)64927-9
|
[6]
|
Prieto, V.G., Mourad-Zeidan, A.A., Melnikova, V., Johnson, M.M., Lopez, A., Diwan, A.H., et al. (2006) Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clinical Cancer Research, 12, 6709-6715.
http://dx.doi.org/10.1158/1078-0432.CCR-06-0758
|
[7]
|
Takenaka, Y., Inohara, H., Yoshii, T., Oshima, K., Nakahara, S., Akahani, S., et al. (2003) Malignant transformation of thyroid follicular cells by galectin-3. Cancer Letters, 195, 111-119.
http://dx.doi.org/10.1016/S0304-3835(03)00056-9
|
[8]
|
Tsuboi, K., Shimura, T., Masuda, N., Ide, M., Tsutsumi, S., Yamaguchi, S., et al. (2007) Galectin-3 expression in colorectal cancer: Relation to invasion and metastasis. Anticancer Research, 27, 2289-2296.
|
[9]
|
Barondes, S.H., Castronovo, V., Cooper, D.N., Cummings, R.D., Drickamer, K., Feizi, T., et al. (1994) Galectins: A family of animal beta-galactoside-binding lectins. Cell, 76, 597-598.
http://dx.doi.org/10.1016/0092-8674(94)90498-7
|
[10]
|
Barondes, S.H., Cooper, D.N., Gitt, M.A. and Leffler, H.G. (1994) Structure and function of a large family of animal lectins. The Journal of Biological Chemistry, 269, 20807-20810.
|
[11]
|
Dumic, J., Dabelic, S. and Flogel, M. (2006) Galectin-3: An open-ended story. Biochim Biophys Acta, 1760, 616-635. http://dx.doi.org/10.1016/j.bbagen.2005.12.020
|
[12]
|
Liu, F.T. and Rabinovich, G.A. (2005) Galectins as modulators of tumour progression. Nature Reviews Cancer, 5, 29-41. http://dx.doi.org/10.1038/nrc1527
|
[13]
|
Shimura, T., Takenaka, Y., Fukumori, T., Tsutsumi, S., Okada, K., Hogan, V., et al. (2005) Implication of galectin-3 in Wnt signaling. Cancer Research, 65, 3535-3537.
http://dx.doi.org/10.1158/0008-5472.CAN-05-0104
|
[14]
|
Shimura, T., Takenaka, Y., Tsutsumi, S., Hogan, V., Kikuchi, A. and Raz, A. (2004) Galectin-3, a novel binding partner of beta-catenin. Cancer Research, 64, 6363-6367.
http://dx.doi.org/10.1158/0008-5472.CAN-04-1816
|
[15]
|
Weinberger, P.M., Adam, B.L., Gourin, C.G., Moretz, W.H., Bollag, R.J., Wang, B.Y., et al. (2007) Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Archives of Otolaryngology—Head and Neck Surgery, 133, 503-510.
http://dx.doi.org/10.1001/archotol.133.5.503
|
[16]
|
Klingensmith, J. and Nusse, R. (1994) Signaling by wingless in Drosophila. Developmental Biology, 166, 396-414.
http://dx.doi.org/10.1006/dbio.1994.1325
|
[17]
|
Zhurinsky, J., Shtutman, M. and Ben-Ze’ev, A. (2000) Plakoglobin and beta-catenin: Protein interactions, regulation and biological roles. Journal of Cell Science, 113, 3127-3139.
|
[18]
|
Zimmerman, Z.F., Kulikauskas, R.M., Bomsztyk, K., Moon, R.T. and Chien, A.J. (2013) Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One, 8, e69593.
http://dx.doi.org/10.1371/journal.pone.0069593
|
[19]
|
Huang, H. and He, X. (2008) Wnt/beta-catenin signaling: New (and old) players and new insights. Current Opinion in Cell Biology, 20, 119-125.
http://dx.doi.org/10.1016/j.ceb.2008.01.009
|
[20]
|
Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S. and Kikuchi, A. (1998) Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO Journal, 17, 1371-1384. http://dx.doi.org/10.1093/emboj/17.5.1371
|
[21]
|
Takenaka, Y., Fukumori, T., Yoshii, T., Oka, N., Inohara, H., Kim, H.R., et al. (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Molecular and Cellular Biology, 24, 4395-4406.
http://dx.doi.org/10.1128/MCB.24.10.4395-4406.2004
|
[22]
|
Correa, M., Machado, J., Carneiro, C.R., Pesquero, J.B., Bader, M., Travassos, L.R., et al. (2005) Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. International Journal of Cancer, 114, 356-363.
http://dx.doi.org/10.1002/ijc.20673
|
[23]
|
Hsu, D.K., Yang, R.Y., Pan, Z., Yu, L., Salomon, D.R., Fung-Leung, W.P., et al. (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. American Journal of Pathology, 156, 1073-1083.
http://dx.doi.org/10.1016/S0002-9440(10)64975-9
|
[24]
|
Tomayko, M.M. and Reynolds, C.P. (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacology, 24, 148-154.
http://dx.doi.org/10.1007/BF00300234
|
[25]
|
Seidal, T., Balaton, A.J. and Battifora, H. (2001) Interpretation and quantification of immunostains. The American Journal of Surgical Pathology, 25, 1204-1207.
http://dx.doi.org/10.1097/00000478-200109000-00013
|
[26]
|
Wick, M.R. and Mills, S.E. (2001) Consensual interpretive guidelines for diagnostic immunohistochemistry. The American Journal of Surgical Pathology, 25, 1208-1210.
http://dx.doi.org/10.1097/00000478-200109000-00014
|
[27]
|
Bonitsis, N., Batistatou, A., Karantima, S. and Charalabopoulos, K. (2006) The role of cadherin/catenin complex in malignant melanoma. Experimental Oncology, 28, 187-193.
|
[28]
|
Kim, H., Lee, J., Hyun, J.W., Park, J.W., Joo, H.G. and Shin, T. (2007) Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biology International, 31, 655-662.
http://dx.doi.org/10.1016/j.cellbi.2006.11.036
|
[29]
|
Krishnan, V., Bane, S.M., Kawle, P.D., Naresh, K.N. and Kalraiya, R.D. (2005) Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clinical & Experimental Metastasis, 22, 11-24.
http://dx.doi.org/10.1007/s10585-005-2036-2
|
[30]
|
Vereecken, P., Debray, C., Petein, M., Awada, A., Lalmand, M.C., Laporte, M., et al. (2005) Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Archives of Dermatological Research, 296, 353-358. http://dx.doi.org/10.1007/s00403-004-0536-6
|
[31]
|
Harhaji, L., Mijatovic, S., Maksimovic-Ivanic, D., Stojanovic, I., Momcilovic, M., Maksimovic, V., et al. (2008) Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: In vitro and in vivo study. Food and Chemical Toxicology, 46, 1825-1833.
http://dx.doi.org/10.1016/j.fct.2008.01.027
|
[32]
|
Wong, R.P., Ng, P., Dedhar, S. and Li, G. (2007) The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Molecular Cancer Therapeutics, 6, 1692-1700.
http://dx.doi.org/10.1158/1535-7163.MCT-07-0134
|
[33]
|
Dietrich, A., Stockmar, C., Aust, G., Endesfelder, S., Guetz, A., Sack, U., et al. (2006) Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model. Journal of Cancer Research and Clinical Oncology, 132, 379-388.
http://dx.doi.org/10.1007/s00432-005-0073-5
|
[34]
|
Mansour, M., Pohajdak, B., Kast, W.M., Fuentes-Ortega, A., Korets-Smith, E., Weir, G.M., et al. (2007) Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. Journal of Translational Medicine, 5, 20.
http://dx.doi.org/10.1186/1479-5876-5-20
|
[35]
|
Coussens, L.M. and Werb, Z. (2002) Inflammation and cancer. Nature, 420, 860-867.
http://dx.doi.org/10.1038/nature01322
|
[36]
|
Califice, S., Castronovo, V., Bracke, M. and van den Brule, F. (2004) Dual activities of galectin-3 in human prostate cancer: Tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene, 23, 7527-7536. http://dx.doi.org/10.1038/sj.onc.1207997
|
[37]
|
Honjo, Y., Inohara, H., Akahani, S., Yoshii, T., Takenaka, Y., Yoshida, J., et al. (2000) Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clinical Cancer Research, 6, 4635-4640.
|
[38]
|
Bachmann, I.M., Straume, O., Puntervoll, H.E., Kalvenes, M.B. and Akslen, L.A. (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research, 11, 8606-8614.
http://dx.doi.org/10.1158/1078-0432.CCR-05-0011
|
[39]
|
Maelandsmo, G.M., Holm, R., Nesland, J.M., Fodstad, Ø. and FlØrenes, V.A. (2003) Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clinical Cancer Research, 9, 3383-3388.
|